DDInter1646 DDInter782
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Saxagliptin {u} (Compound) resembles {v} (Compound) Vildagliptin
Saxagliptin {u} (Compound) binds {v} (Gene) DPP8
Saxagliptin {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Saxagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Saxagliptin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Saxagliptin (Compound) resembles Vildagliptin (Compound)
Saxagliptin (Compound) binds DPP8 (Gene)
Saxagliptin (Compound) causes Upper respiratory tract infection (Side Effect)
Saxagliptin may cause a minor interaction that can limit clinical effects when taken with Modafinil
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Saxagliptin may lead to a major life threatening interaction when taken with Bexarotene